Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06391450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Study acronym: EMPA-PKD
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  2. Study Identification, Study Status, Oversight, IPDSharingv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Mar 2027 to May 2027
    • Start date changed from estimate of May 2024 to Jun 14, 2024
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
Trial Details
NCT Number NCT06391450
Lead Sponsor Hannover Medical School
Collaborators: Boehringer Ingelheim
Conditions
(from sponsor)		 Autosomal Dominant Polycystic Kidney
Related terms Polycystic Kidney, Autosomal Dominant
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov